Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study
Authors' conclusion
The clinical manifestation of (GH+TSH)oma and (GH+PRL)oma may be atypical. When screening for pituitary adenomas, a comprehensive evaluation of all pituitary target gland hormones is needed. Cosecreting pituitary GH adenomas are more aggressive and surgery is often unable to completely remove the tumor, requiring pharmacologic or radiological treatment if necessary. Clinicians should give high priority to biochemical remission, although solo part remission may occur.
Study context
- Population
- Patients with pituitary growth hormone (GH) adenomas cosecreting thyroid stimulating hormone (TSH) or prolactin (PRL), Beijing Tiantan Hospital, January 2009–January 2023
- Participants
- 22 / 10 / 335 / 49
- Comparison
- Cosecreting GH adenomasoma,oma) vs solo-secreting GHoma and TSHoma
- (GH+TSH)oman = 22
- (GH+PRL)oman = 10
- GHoman = 335reference
- TSHoman = 49reference
- Outcome
- Clinical characteristics of cosecreting GH adenomas
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Cosecreting GH adenomas had various clinical manifestations, larger tumor volume, and were more likely to invade the cavernous sinus bilaterally and compress the optic chiasm
- GH and TSH levels were lower in (GH+TSH)oma than in GHoma or TSHoma
Observational data: associations, not effects.
Further findings
- Solo part remission was observed in both (GH+TSH)oma and (GH+PRL)oma
- Cavernous sinus invasion was an independent risk factor for biochemical nonremission in (GH+TSH)oma and (GH+PRL)oma
Original publication
Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study. Endocr Pract. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →